The cephalosporin drugs market is projected to register a CAGR of 2.75% during the forecast period, with a revenue of approximately USD 14,010 million in 2020 and expected to reach USD 16,490 million by 2026.
There are various studies that have found that the higher cephalosporin consumption rate and use ratio has made lower morbidity and mortality caused by COVID-19 than other antibacterials. However, cephalosporins have suggested inhibiting the SARS-CoV-2 and the results of the study and the effective cases imply that cephalosporins may work against the SARS-CoV-2 virus. Also, the cephalosporins in combinations with macrolides, and quinolones may be potentially effective against COVID-19 (SARS-CoV-2). Therefore there are in vitro and in vivo studies that are going on to evaluate the potential of generations of cephalosporin for COVID-19.
The market is expected to grow due to the increasing demand for anti-microbials in various indications, the rising prevalence of infectious diseases, and the increase in funding for the development of antibiotics. The market is also attributed to the increase in consumption of cephalosporin, easier availability, and a rise in demand for over-the-counter drugs.
According to the Centers for Disease Control and Prevention (CDC), in 2019, a total of 8,920 new cases of tuberculosis (TB) were reported in the United States, representing an incidence rate of 2.7 cases per 100,000 population. As per the US Department of Health & Human Services report 2020 there are about 37,832 people in the United States were diagnosed with HIV in 2018, and 38,000 new HIV infections still occur in the United States. It has also been reported that there is a rapid spread of various infectious diseases that is fueling the market growth.
The increasing number of clinical trials for R&D of cephalosporin drugs is also expected to propel the growth of the cephalosporin drugs market over the forecast period. For instance, in September 2018, National Institutes of Health (NIH) has granted USD 9.4 million for establishing the Center for Biomedical Research Excellence (COBRE) to address the worldwide threat of drug-resistant pathogens.
Additionally, there are also companies are involved in the strategic development of new products, for example, in April 2018, Basilea Pharmaceutica Ltd. announced that its partner Avir Pharma Inc. launched Basilea's hospital antibiotic Zevtera (ceftobiprole) in Canada. Hence all these factors has helped the cephalosporin drugs market to witness a high growth over the forecast period.
Key Market Trends
The Fifth-generation Segment is Expected to Witness a Healthy Growth Over the Forecast Period
The fifth-generation cephalosporins are found to be developed in the lab to specifically target resistant strains of bacteria. The fifth-generation cephalosporins are found including Ceftobiprole, Ceftaroline, and Ceftolozane. The ceftobiprole is found to be effective against methicillin-resistant staphylococcus aureus (MRSA).
The outbreak of the COVID-19 pandemic has shown an increase in the rising number of infectious diseases that has impelled the pharmaceutical industry to develop both therapeutic and preventive interventions. The burden of infectious diseases across the world is increasing, which is resulting in the rising focus on diagnosis and treatment of the same. According to the UNAIDS, during 2019, the number of new HIV/AIDS cases found in the world was around 1.7 million, and about 38 million people were living with HIV worldwide in the same year.
Ceftobiprole has antipseudomonal characteristics that appear to be less susceptible to the development of resistance. Ceftaroline has also been described as the fifth-generation cephalosporin but does not have the antipseudomonal or VRE coverage of ceftobiprole. The fifth-generation cephalosporins are not active against Pseudomonas species.
The market is thus found growing as it has opened gates for an alternative for the treatment of complicated intra-abdominal infections and complicated urinary tract infections. Furthermore, Ceftolozane is also combined with the B-lactamase inhibitor tazobactam, as multi-drug resistant bacterial infections generally exhibit resistance to all B-lactam antibiotics, unless this enzyme is inhibited. Hence, the rising use of combination therapies helps to drive the market during the forecast period.
In March 2018, Basilea Pharmaceutica Ltd. has announced today that partner Grupo Biotoscana S.L. has launched Basilea's hospital antibiotic Zevtera (ceftobiprole) in Argentina. Also, there has been a notable increase in the fifth generation cephalosporin drugs such as Ceftobiprole and Ceftaroline that has been attributed to their ability to kill a wide range of bacterias.
Asia-Pacific is Expected to be the Fastest Growing Segment in the Global Market
Asia-Pacific is expected to show high growth due to the rising prevalence of infectious diseases, increasing healthcare expenditure, and a large population base. Furthermore, Cefuroxime is a second-generation cephalosporin antibiotic that has a broad-spectrum activity and is commonly used for the treatment of both upper and lower respiratory tract infections, Lyme disease, and genitourinary tract infections. It is being readily available and affordable, and it exists in both oral and parenteral forms respectively.
The COVID-19 has shown a slight impact on this market as the cephalosporins have not been proven much effective against viruses. B-lactam antibiotics including cephalosporins have a bacteriostatic effect. The bacteriostatic action means the action of suppressing the growth of bacteria. B-lactam antibiotics act by inhibiting peptidoglycan synthase, which is an enzyme required for synthesizing bacterial cell walls. However, cephalosporins suggest inhibiting SARS-CoV-2 but have a slight impact on the market growth.
In China, tuberculosis is the leading cause of death from infectious disease among adults. According to the World Health Organization in 2019, 8,33,000 people fell ill with tuberculosis in China. However, China is still among the 30 high-burden tuberculosis countries in the world, and tuberculosis remains a public health concern. The rising cases of tuberculosis are expected to boost the overall growth of the market.
Also, there is an increase in consumption of cephalosporin, easier availability, and a rise in demand for over-the-counter drugs, and an increase in bacterial infection in the region that helps in driving the market growth.
The cephalosporin drugs market is fragmented in terms of competition, owing to the presence of many small and large companies. There are also various collaborations, agreements, partnerships, and new product launches that are some of the important strategies adopted by the market players. Some of the well-known players in the market studied include Astellas Pharma Inc., Baxter International, F. Hoffmann-La Roche AG, GlaxoSmithKline PLC, Lupin Pharmaceuticals, Macleods Pharmaceuticals Ltd., Mankind Pharma, Merck & Co. Inc., Pfizer Inc., and Teva Pharmaceuticals. Therefore the increasing number of clinical trials for R&D of cephalosporin drugs by these companies is expected to propel the growth of the global cephalosporin drugs market over the forecast period.
Reasons to Purchase this report:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
TABLE OF CONTENTS
- 1.1 Study Deliverables
- 1.2 Study Assumptions
- 1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
- 4.1 Market Overview
- 4.2 Market Drivers
- 4.2.1 Rising Demand for Anti-microbials in Various Indications
- 4.2.2 Rising Prevalence of Infectious Diseases
- 4.2.3 Increase in Funding for the Development of Antibiotics
- 4.3 Market Restraints
- 4.3.1 Stringent Regulatory Guidelines
- 4.3.2 Side Effects Associated with Cephalosporin
- 4.4 Porter's Five Forces Analysis
- 4.4.1 Threat of New Entrants
- 4.4.2 Bargaining Power of Buyers/Consumers
- 4.4.3 Bargaining Power of Suppliers
- 4.4.4 Threat of Substitute Products
- 4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
- 5.1 By Generation
- 5.1.1 First-generation
- 5.1.2 Second-generation
- 5.1.3 Third-generation
- 5.1.4 Fourth-generation
- 5.1.5 Fifth-generation
- 5.2 By Prescription Type
- 5.2.1 Prescription Drugs
- 5.2.2 OTC Drugs
- 5.3 Geography
- 5.3.1 North America
- 184.108.40.206 United States (By Generation, and By Prescription Type)
- 220.127.116.11 Canada (By Generation, and By Prescription Type)
- 18.104.22.168 Mexico (By Generation, and By Prescription Type)
- 5.3.2 Europe
- 22.214.171.124 Germany (By Generation, and By Prescription Type)
- 126.96.36.199 United Kingdom (By Generation, and By Prescription Type)
- 188.8.131.52 France (By Generation, and By Prescription Type)
- 184.108.40.206 Italy (By Generation, and By Prescription Type)
- 220.127.116.11 Spain (By Generation, and By Prescription Type)
- 18.104.22.168 Rest of Europe (By Generation, and By Prescription Type)
- 5.3.3 Asia-Pacific
- 22.214.171.124 China (By Generation, and By Prescription Type)
- 126.96.36.199 Japan (By Generation, and By Prescription Type)
- 188.8.131.52 India (By Generation, and By Prescription Type)
- 184.108.40.206 Australia (By Generation, and By Prescription Type)
- 220.127.116.11 South Korea (By Generation, and By Prescription Type)
- 18.104.22.168 Rest of Asia-Pacific (By Generation, and By Prescription Type)
- 5.3.4 Middle East and Africa
- 22.214.171.124 GCC (By Generation, and By Prescription Type)
- 126.96.36.199 South Africa (By Generation, and By Prescription Type)
- 188.8.131.52 Rest of Middle East and Africa (By Generation, and By Prescription Type)
- 5.3.5 South America
- 184.108.40.206 Brazil (By Generation, and By Prescription Type)
- 220.127.116.11 Argentina (By Generation, and By Prescription Type)
- 18.104.22.168 Rest of South America (By Generation, and By Prescription Type)
6 COMPETITIVE LANDSCAPE
- 6.1 Company Profiles
- 6.1.1 Aristo Pharmaceuticals Ltd
- 6.1.2 Baxter International
- 6.1.3 F. Hoffmann-La Roche AG
- 6.1.4 GlaxoSmithKline PLC
- 6.1.5 Lupin Pharmaceuticals Inc.
- 6.1.6 Macleods Pharmaceuticals Ltd
- 6.1.7 Mankind Pharma
- 6.1.8 Merck & Co. Inc.
- 6.1.9 Pfizer Inc.
- 6.1.10 Teva Pharmaceutical Industries Ltd
- 6.1.11 Bristol-Myers Squibb Company
- 6.1.12 Eli Lilly and Company
- 6.1.13 Sun Pharmaceutical
- 6.1.14 Basilea Pharmaceutica Ltd.
- 6.1.15 Abbvie Inc. (Allergan PLC)
7 MARKET OPPORTUNITIES AND FUTURE TRENDS